BMS’ Orencia (abatacept) Receive the FDA’s Breakthrough Therapy Designation to Prevent Acute Graft-Versus-Host Disease After Stem Cell Transplant

 BMS’ Orencia (abatacept) Receive the FDA’s Breakthrough Therapy Designation to Prevent Acute Graft-Versus-Host Disease After Stem Cell Transplant

BMS’ Orencia (abatacept) Receive the FDA’s Breakthrough Therapy Designation to Prevent Acute Graft-Versus-Host Disease After Stem Cell Transplant

Shots:

  • The US FDA BT’s designation is based on P-II study assessing the impact of Orencia on the prevention of severe acute GvHD when added to a standard GvHD prophylactic regimen in patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or mismatched donor
  • A BT designation is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition
  • Orencia is an immunomodulator targeting proteins involved in co-stimulation, thus inhibiting T-cell activation and is an approved therapy to treat multiple RA conditions. If approved by FDA, Orencia will be the first approved therapy to prevent acute GvHD

Click here to­ read full press release/ article | Ref: BMS | Image: GEN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post